Fig. 1: Nuclear factor erythroid 2-related factor 2 (Nrf2) activation is increased in clinically relevant radioresistant (CRR) cells. | Laboratory Investigation

Fig. 1: Nuclear factor erythroid 2-related factor 2 (Nrf2) activation is increased in clinically relevant radioresistant (CRR) cells.

From: The antioxidative stress regulator Nrf2 potentiates radioresistance of oral squamous cell carcinoma accompanied with metabolic modulation

Fig. 1

A The surviving fractions of SAS cells, HSC-2 cells, and their respective clinically relevant radioresistant (CRR) clones after exposure to 2, 6, and 10 Gy of X-ray radiation were evaluated using a modified high-density survival assay. *p < 0.05 and **p < 0.01. B The mRNA levels of Nrf2 in SAS cells, HSC-2 cells, and their respective CRR clones under normal conditions were analyzed by real-time quantitative polymerase chain reaction. The results are presented as the mean ± SD of three independent experiments. *p < 0.05 and **p < 0.01. C The protein expression of Nrf2, phosphorylated Nrf2 (phospho-Nrf2), Keap1, phosphorylated p62 (phospho-p62), STAT3, and phosphorylated STAT3 (phospho-STAT3) in SAS, HSC-2, and CRR cells under normal conditions. Whole-cell and nuclear protein was prepared, and the expression of Nrf2, phospho-Nrf2, Keap1, phospho-p62, STAT3, and phospho-STAT3 was examined via Western blotting. D Representative microscopic images of H&E and immunohistochemical staining of phospho-Nrf2 and Ki-67 in oral squamous cell carcinoma tissues excised on day 21 after xenotransplantation. Original magnification, ×100; bar, 100 µm. Phospho-Nrf2 and Ki-67 were quantified using ImageJ software.

Back to article page